
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FOLOTYN | Acrotech Biopharma | N-022468 RX | 2009-09-24 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| folotyn | New Drug Application | 2024-09-26 |
| histex pdx drops | C200263 | 2024-01-08 |
| pralatrexate | NDA authorized generic | 2022-11-15 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| t-cell lymphoma peripheral | — | D016411 | — |
Code | Description |
|---|---|
| J9307 | Injection, pralatrexate, 1 mg |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| T-cell lymphoma peripheral | D016411 | — | — | 2 | 3 | 1 | — | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 4 | 2 | — | — | — | 5 |
| Recurrence | D012008 | — | — | 3 | 2 | — | — | — | 4 |
| T-cell lymphoma | D016399 | — | — | 3 | 2 | — | — | — | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 1 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sezary syndrome | D012751 | — | C84.1 | 2 | — | — | — | — | 2 |
| Mycosis fungoides | D009182 | — | C84.0 | 2 | — | — | — | — | 2 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 2 | — | — | — | — | 2 |
| Mucositis | D052016 | EFO_1001898 | — | 2 | — | — | — | — | 2 |
| Primary cutaneous anaplastic large cell lymphoma | D054446 | — | C86.6 | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | — | 1 |
| Drug common name | Pralatrexate |
| INN | pralatrexate |
| Description | Pralatrexate is a pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma. It has a role as an antineoplastic agent, an antimetabolite and an EC 1.5.1.3 (dihydrofolate reductase) inhibitor. It is a N-acyl-L-glutamic acid, a member of pteridines and a terminal acetylenic compound. |
| Classification | Small molecule |
| Drug class | antimetabolites (folic acid derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1 |
| PDB | — |
| CAS-ID | 146464-95-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201746 |
| ChEBI ID | 71223 |
| PubChem CID | 148121 |
| DrugBank | DB06813 |
| UNII ID | A8Q8I19Q20 (ChemIDplus, GSRS) |



